Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Australia's Biosimilar Substitution Policy Under Fire As Etanercept Product Is 'A'-Flagged

Executive Summary

Australia's new policy of 'a'-flagging biosimilars, or allowing them to be substituted for the prescribed originator drug in the pharmacy, is coming under fire amid concerns that the move is overly driven by economic considerations and may not be the most appropriate way of improving patient access to cheaper biologic medicines.


Related Content

Samsung Bioepis’s Biosimilar Enbrel ‘Substitutable’ In Australia As Pfizer Patent Case Is Rebuffed
Brazil: The Next Hot Spot For Biosimilar Substitution?
Australian Survey Reveals Biosimilar Awareness, Switching Concerns
Inflectra to be first 'substitutable' biosimilar in Australia


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts